Clinical trial · Interventional
Apatinib for the Elderly Advanced Gastric Cancer
A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
NCT03104283CI-TRIAL-00057104completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of our study is to assess the efficacy and safety of apatinib in elderly advanced gastric cancer patients, and to find the relationship between the expression of VEGFR-2 and efficacy of apatinib treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Apatinib Group
- description
- take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
- interventionNames
- Drug: Apatinib
Primary outcomes (1)
- measure
- Progression-free survival (PFS)
- timeFrame
- 1 year
- description
- PFS was defined to be the time from registration to the date of disease progress sion or death resulting from any cause.
Secondary outcomes (3)
- measure
- Objective response rate (ORR)
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction; 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 3. Progression with or intolerance to one or more lines of chemotherapy; 4. At least one measurable lesion as defined by RECIST 1.1; 5. With acceptable hematologic, cardiac, hepatic, pulmonary and renal function; 6. Can take apatinib orally; 7. Estimated life expectancy ≥ 3 months. Exclusion Criteria: 1. Patients cannot take apatinib orally for any reason; 2. Patients with uncontrolled central nervous system (CNS) metastases; 3. Patients with massive hydrothorax or ascites; 4. Proteinuria 2+ or 24-hour urinary protein ≥ 1g; 5. Newly-happened traumatism or pathological fracture; 6. Estimated life expectancy ˂ 3 months; 7. Received chemotherapy in the past 28 days before enrollment; 8. Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg); 9. Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).
References
Publications (0)
Data not yet available
No reference posted for this study.